Cargando…
Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial
BACKGROUND: Subtle neurodegenerative motor and cognitive impairments accumulate over a prodromal period several years before clinical diagnosis of Huntington's disease (HD). The inclusion of prodromal individuals in therapeutic trials would facilitate testing of therapies early in the disease c...
Autores principales: | Langbehn, Douglas R., Fine, Elisabeth M., Meier, Andreas, Hersch, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306552/ https://www.ncbi.nlm.nih.gov/pubmed/35170086 http://dx.doi.org/10.1002/mds.28944 |
Ejemplares similares
-
Clinical Outcomes and Selection Criteria for Prodromal Huntington's Disease Trials
por: Langbehn, Douglas R., et al.
Publicado: (2020) -
Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children
por: Byrne, Lauren M., et al.
Publicado: (2022) -
Hypertension, Antihypertensive Use and the Delayed‐Onset of Huntington's Disease
por: Steventon, Jessica J., et al.
Publicado: (2020) -
Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington's Disease
por: Stoker, Thomas B., et al.
Publicado: (2020) -
Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease
por: Niemela, Valter, et al.
Publicado: (2020)